Testing three investigational drugs for mouth and lung cancers
Part of Cancer clinical trials.
This trial tests whether PRV111, PRV211, and PRV131 are safe and work better than expected for certain mouth (lip/oral cavity) cancers and lung cancers. It may help by trying a new approach given directly to the tumor and then monitoring how well it shrinks and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a confirmed mouth (lip/oral cavity) or lung cancer matching the trial stage
- Your tumor must be reachable for treatment (mouth surgery within 8 weeks, or lung injection using a bronchoscope)
- Your tumor must be measurable by exam or scans
- You must be healthy enough for treatment (ECOG performance status 0–2) and expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) given before surgery to treat mouth or throat cancer that has come back. The goal is to shrink the tumor and improve surgery outcomes.
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
This trial tests whether giving a type of radiation therapy (proton or photon) along with the immunotherapy drug pembrolizumab before surgery is safe and effective for people with certain oral cavity cancers. The goal is to see if this combination can shrink the tumor and improve outcomes.
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
Hear when a new Oral Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.